FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1670-1679 November 25, 1999 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Mazurek, A. A. PubMed Citation

Alzheimer's disease, which is characterized by progressive loss of memory and cognitive function, affects 15 million people worldwide. The incidence increases steadily from 0.5 percent per year at the age of 65 years to nearly 8 percent per year after the age of 85 years.¹ Because survival for a decade is common, the prevalence increases from 3 percent at the age of 65 years to 47 percent after the age of 85 years.² Mutations in the gene for the amyloid precursor protein and the genes for presenilin 1 and 2 cause rare, dominantly inherited forms of the disease occurring before . . . [Full Text of this Article]

Methodologic Considerations

Cholinergic Augmentation Therapy

Physostigmine

Tacrine

Donepezil

Metrifonate

Rivastigmine

Eptastigmine

Efficacy of Cholinesterase-Inhibitor Drugs

Slowing the Progression of Alzheimer's Disease

Alpha-Tocopherol and Selegiline

Idebenone

Propentofylline

Ginkgo biloba

Acetyl-L-Carnitine

Social Interventions

Efficacy of Treatments to Delay Disease Progression

Treatment of the Behavioral Manifestations of Alzheimer's Disease

Depression

Delusions and Psychosis

Cholinergic Drugs and Behavioral Manifestations

Sleep Disturbance

Wandering

Prevention

Conclusions

Source Information

From the Taub Institute on Alzheimer's Disease and the Aging Brain, the Gertrude H. Sergievsky Center, the Departments of Neurology and Psychiatry, College of Physicians and Surgeons, and the Division of Epidemiology, School of Public Health, Columbia University, New York.

Address reprint requests to Dr. Mayeux at Columbia University, 630 W. 168th St., New York, NY 10032, or at rpm2@columbia.edu.

References

Related Letters:

Treatment of Alzheimer's Disease
Mazurek A. A., De Deyn P. P., Mayeux R., Sano M.
Extract | Full Text  
N Engl J Med 2000; 342:821-822, Mar 16, 2000. Correspondence

This article has been cited by other articles:

• LoConte, N. K., Gleason, C. E., Gunter-Hunt, G., Carlsson, C. M., Siebers, M. (2008). Standardized Note Template Improves Screening of Firearm Access and Driving Among Veterans With Dementia. AM J ALZHEIMERS DIS OTHER DEMEN 23: 313-318 [Abstract]  
• Karlawish, J., Kim, S. Y. H., Knopman, D., van Dyck, C. H., James, B. D., Marson, D. (2008). Interpreting the Clinical Significance of Capacity Scores for Informed Consent in Alzheimer Disease Clinical Trials. AJGP 16: 568-574 [Abstract] [Full Text]  
• Swanson, K. A., Carnahan, R. M. (2007). Dementia and Comorbidities: An Overview of Diagnosis and Management. Journal of Pharmacy Practice 20: 296-317 [Abstract]  
• Bassett, S. S., Yousem, D. M., Cristinzio, C., Kusevic, I., Yassa, M. A., Caffo, B. S., Zeger, S. L. (2006). Familial risk for Alzheimer's disease alters fMRI activation patterns. Brain 129: 1229-1239 [Abstract] [Full Text]  
• Moreira, P. I., Honda, K., Zhu, X., Nunomura, A., Casadesus, G., Smith, M. A., Perry, G. (2006). Brain and brawn: Parallels in oxidative strength. Neurology 66: S97-S101 [Abstract] [Full Text]  
• Frisoni, G. B., Filippi, M. (2005). Multiple Sclerosis and Alzheimer Disease through the Looking Glass of MR Imaging. Am. J. Neuroradiol. 26: 2488-2491 [Full Text]  
• Farlow, M. R. (2005). The search for disease modification in moderate to severe Alzheimer disease: A critical review of current evidence. Neurology 65: S25-S30 [Full Text]  
• Gillette-Guyonnet, S., Andrieu, S., Nourhashemi, F., de La Gueronniere, V., Grandjean, H., Vellas, B. (2005). Cognitive impairment and composition of drinking water in women: findings of the EPIDOS Study. Am. J. Clin. Nutr. 81: 897-902 [Abstract] [Full Text]  
• Molinuevo, J. L., Llado, A., Rami, L. (2005). Memantine: Targeting glutamate excitotoxicity in Alzheimer's disease and other dementias. AM J ALZHEIMERS DIS OTHER DEMEN 20: 77-85 [Abstract]  
• Albensi, B. C., Igoechi, C., Janigro, D., Ilkanich, E. (2004). Why do many NMDA antagonists fail, while others are safe and effective at blocking excitotoxicity associated with dementia and acute injury?. AM J ALZHEIMERS DIS OTHER DEMEN 19: 269-274 [Abstract]  
• Rockwood, K (2004). Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75: 677-685 [Abstract] [Full Text]  
• Selkoe, D. J. (2004). Alzheimer Disease: Mechanistic Understanding Predicts Novel Therapies. ANN INTERN MED 140: 627-638 [Full Text]  
• Bartels, S. J., Dums, A. R., Oxman, T. E., Schneider, L. S., Arean, P. A., Alexopoulos, G. S., Jeste, D. V. (2004). Evidence-Based Practices in Geriatric Mental Health Care. Focus 2: 268-281 [Abstract] [Full Text]  
• Molinuevo, J. L., Garcia-Gil, V., Villar, A. (2004). Memantine: An antiglutamatergic option for dementia. AM J ALZHEIMERS DIS OTHER DEMEN 19: 10-18 [Abstract]  
• Krishnan, K. R. R., Charles, H. C., Doraiswamy, P. M., Mintzer, J., Weisler, R., Yu, X., Perdomo, C., Ieni, J. R., Rogers, S. (2003). Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer's Disease. Am. J. Psychiatry 160: 2003-2011 [Abstract] [Full Text]  
• (2003). {blacktriangledown}Memantine for dementia?. DTB 41: 73-76 [Abstract] [Full Text]  
• Lanctot, K. L., Herrmann, N., Yau, K. K., Khan, L. R., Liu, B. A., LouLou, M. M., Einarson, T. R. (2003). Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 169: 557-564 [Abstract] [Full Text]  
• Rosenthal, T. C., Khotianov, N. (2003). Managing Alzheimer Dementia Tomorrow. J Am Board Fam Med 16: 423-434 [Abstract] [Full Text]  
• Hirono, N., Hashimoto, M., Yasuda, M., Kazui, H., Mori, E. (2003). Accelerated Memory Decline in Alzheimer's Disease With Apolipoprotein {epsilon}4 Allele. J. Neuropsychiatry Clin. Neurosi. 15: 354-358 [Abstract] [Full Text]  
• Clark, C. M., Karlawish, J. H.T. (2003). Alzheimer Disease: Current Concepts and Emerging Diagnostic and Therapeutic Strategies. ANN INTERN MED 138: 400-410 [Abstract] [Full Text]  
• Luchsinger, J. A., Tang, M.-X., Shea, S., Mayeux, R. (2003). Antioxidant Vitamin Intake and Risk of Alzheimer Disease. Arch Neurol 60: 203-208 [Abstract] [Full Text]  
• in 't Veld, B. A., Launer, L. J., Breteler, M. M. B., Hofman, A., Stricker, B. H. Ch. (2002). Pharmacologic Agents Associated with a Preventive Effect on Alzheimer's Disease: A Review of the Epidemiologic Evidence. Epidemiol Rev 24: 248-268 [Full Text]  
• Rockwood, K, Graham, J E, Fay, S (2002). Goal setting and attainment in Alzheimer's disease patients treated with donepezil. J. Neurol. Neurosurg. Psychiatry 73: 500-507 [Abstract] [Full Text]  
• Bartels, S. J., Dums, A. R., Oxman, T. E., Schneider, L. S., Arean, P. A., Alexopoulos, G. S., Jeste, D. V. (2002). Evidence-Based Practices in Geriatric Mental Health Care. Psychiatr. Serv. 53: 1419-1431 [Abstract] [Full Text]  
• Nobili, F., Koulibaly, M., Vitali, P., Migneco, O., Mariani, G., Ebmeier, K., Pupi, A., Robert, P. H., Rodriguez, G., Darcourt, J. (2002). Brain Perfusion Follow-Up in Alzheimer's Patients During Treatment with Acetylcholinesterase Inhibitors. JNM 43: 983-990 [Abstract] [Full Text]  
• Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Wilson, R. S. (2002). Vitamin E and Cognitive Decline in Older Persons. Arch Neurol 59: 1125-1132 [Abstract] [Full Text]  
• Greicius, M D, Geschwind, M D, Miller, B L (2002). Presenile dementia syndromes: an update on taxonomy and diagnosis. J. Neurol. Neurosurg. Psychiatry 72: 691-700 [Abstract] [Full Text]  
• Trojanowski, J. Q. (2002). Neuropathological Verisimilitude in Animal Models of Alzheimer's Disease : Key to Elucidating Neurodegenerative Pathways and Identifying New Targets for Drug Discovery. Am. J. Pathol. 160: 409-411 [Full Text]  
• Dik, M. G., Jonker, C., Comijs, H. C., Bouter, L. M., Twisk, J. W.R., van Kamp, G. J., Deeg, D. J.H. (2001). Memory complaints and APOE-{epsilon}4 accelerate cognitive decline in cognitively normal elderly. Neurology 57: 2217-2222 [Abstract] [Full Text]  
• FRISONI, G B (2001). Structural imaging in the clinical diagnosis of Alzheimer's disease: problems and tools. J. Neurol. Neurosurg. Psychiatry 70: 711-718 [Full Text]  
• Demers, L., Oremus, M., Perrault, A., Champoux, N., Wolfson, C. (2000). Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Psychometric Properties of Functional and Quality of Life Scales. J Geriatr Psychiatry Neurol 13: 170-180 [Abstract]  
• Mayeux, R., Small, S. A. (2000). Finding the Beginning or Predicting the Future?. Arch Neurol 57: 783-784 [Full Text]  
• Mazurek, A. A., De Deyn, P. P., Mayeux, R., Sano, M. (2000). Treatment of Alzheimer's Disease. NEJM 342: 821-822 [Full Text]  
• (2000). New Treatments for Alzheimer's Disease Reviewed. JWatch Neurology 2000: 3-3 [Full Text]  
• Xu, J., Chen, S., Ahmed, S. H., Chen, H., Ku, G., Goldberg, M. P., Hsu, C. Y. (2001). Amyloid-{beta} Peptides Are Cytotoxic to Oligodendrocytes. J. Neurosci. 21: RC118-RC118 [Abstract] [Full Text]